You just read:

S*BIO's Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies

News provided by

S*BIO

Dec 07, 2010, 08:00 EST